Rivoceranib Mesylate

Drug Overview

Rivoceranib mesylate (also known internationally as apatinib) is an advanced, oral “Smart Drug” designed to fight cancer. It belongs to a specialized group of medicines known as Targeted Therapy. Unlike older chemotherapy treatments that attack all fast-growing cells in the body, rivoceranib is specifically engineered to starve tumors by cutting off their blood supply.

In the global corporate healthcare landscape, rivoceranib represents a major step forward in precision oncology. By targeting the exact mechanisms that tumors use to grow new blood vessels, it offers a highly focused treatment option. It is currently being studied heavily in combination with Immunotherapy to treat aggressive liver cancers and other solid tumors in international markets, including the US and Europe.

• Generic Name: Rivoceranib mesylate
• US Brand Names: None (Currently an investigational drug in the US; marketed as Aitan in China)
• Drug Class: Tyrosine Kinase Inhibitor (TKI); Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Investigational (Currently under FDA review for specific cancers; holds Orphan Drug Designation)

What Is It and How Does It Work? (Mechanism of Action)

To understand how rivoceranib works, imagine a tumor as a rapidly growing weed. To survive and spread, the weed needs a constant supply of water and nutrients. Tumors trick the body into building new “pipes” (blood vessels) directly to them—a process called angiogenesis. Rivoceranib acts as a specialized tool that blocks the construction of these new pipes, effectively starving the cancer cells.

At the molecular level, rivoceranib’s mechanism is highly precise:

1. Targeting the Receptor: The drug travels through the bloodstream and specifically seeks out a protein receptor called VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), which is found on the surface of blood vessel cells.
2. Blocking Energy (ATP Binding): Riviceranib enters the cell and binds tightly to the intracellular “energy pocket” (the ATP-binding site) of the VEGFR2 protein.
3. Shutting Down the Signal: By occupying this pocket, the drug prevents the receptor from activating (phosphorylation). This shuts down the critical downstream communication lines, specifically the MAPK/ERK and PI3K/AKT signaling pathways.
4. Halting Angiogenesis: Without these signals, the cells that line the blood vessels (endothelial cells) cannot multiply or migrate to form new vessels. The tumor is deprived of oxygen and nutrients, causing it to stop growing or shrink.

FDA-Approved Clinical Indications

Because rivoceranib is an investigational agent in the United States, it is currently utilized in clinical trials and is under FDA review. It has not yet received final FDA approval for general prescription, though it is approved in other countries.

Oncological Uses (Investigational)

• Unresectable Hepatocellular Carcinoma (uHCC): Liver cancer that cannot be removed by surgery. It is heavily studied as a first-line treatment in combination with the immunotherapy drug camrelizumab.
• Gastric (Stomach) Cancer: Investigated for advanced or metastatic stomach cancers after other treatments have failed.
• Adenoid Cystic Carcinoma: Studied as a standalone treatment for this rare type of head and neck cancer.
• Colorectal Cancer: Researched in combination with other anti-cancer drugs.

Non-Oncological Uses

• There are currently no non-oncological uses for rivoceranib.

Dosage and Administration Protocols

Rivoceranib is taken by mouth, allowing patients the convenience of managing their targeted therapy at home under close medical supervision.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: Because the liver processes this drug, patients with moderate to severe liver issues require close monitoring. The dose is often reduced if liver enzymes (like AST or ALT) become dangerously elevated.
• Renal (Kidney) Insufficiency: Standard doses are generally used for mild kidney issues. However, if patients develop high levels of protein in their urine (proteinuria), the dose may be reduced or paused.

Clinical Efficacy and Research Results

Recent clinical data published between 2023 and 2025 highlights the drug’s powerful effects, particularly when combined with immunotherapy. The global Phase 3 CARES-310 trial provided landmark results for liver cancer (uHCC).

• Overall Survival (OS): In the final analysis of the CARES-310 trial, patients taking rivoceranib combined with camrelizumab achieved a median overall survival of 23.8 months, compared to just 15.2 months for those on the standard drug sorafenib.
• Long-Term Survival Rates: Numerical data showed a 24-month survival rate of 49.0% for the combination therapy, meaning nearly half of the patients were alive at two years. The 36-month survival rate was an impressive 37.7%.
• Disease Progression: The combination therapy significantly extended the time patients lived without their cancer growing (Progression-Free Survival), achieving a median of 5.6 months versus 3.7 months for the older standard of care.

Safety Profile and Side Effects

Black Box Warning:

None. (As an investigational drug in the US, it does not currently carry a formal FDA Black Box Warning, though it is closely monitored for severe bleeding and liver toxicity typical of VEGFR inhibitors).

Common Side Effects (>10%)

• Hypertension: High blood pressure (one of the most common signs the drug is working on blood vessels).
• Palmar-Plantar Erythrodysesthesia: Redness, swelling, pain, or peeling on the palms of the hands and soles of the feet (Hand-Foot Syndrome).
• Proteinuria: Excess protein leaking into the urine.
• Elevated Liver Enzymes: Increases in AST and ALT, indicating mild liver stress.
• Fatigue: Feeling unusually tired.

Serious Adverse Events

• Hemorrhage: Severe bleeding events, including gastrointestinal bleeding.
• Gastrointestinal Perforation: A rare but dangerous hole forming in the stomach or intestine.
• Severe Hepatotoxicity: Serious liver damage requiring immediate medical intervention.

Management Strategies

• Blood Pressure Control: Patients are often prescribed standard blood pressure medications to keep hypertension in check while staying on the cancer drug.
• Hand and Foot Care: Using thick, urea-based moisturizing creams and wearing soft socks can prevent and soothe Hand-Foot Syndrome.

Research Areas

In the fields of Oncology and Regenerative Medicine, rivoceranib mesylate is a key focus for “Tumor Microenvironment Normalization.” Scientists are investigating how to use this drug alongside advanced Immunotherapy (such as camrelizumab) and engineered stem-cell treatments to overcome the chaotic, leaky blood vessel defenses of solid tumors. Current research (2026) is looking at how rivoceranib’s precise VEGFR2-blocking ability not only starves the cancer of its blood supply but also temporarily “normalizes” these vessels, potentially creating a clear pathway that allows a flood of regenerative immune cells to directly infiltrate and destroy aggressive diseases like liver cancer (uHCC) for long-term survival.

Disclaimer: The oncology research discussed is based on preclinical or early investigational phase studies, including ongoing clinical research. The mechanisms and potential applications described are still under evaluation and are not established for routine clinical use. This content is intended for scientific and educational purposes only. 

Connection to Stem Cell and Regenerative Medicine

In the evolving fields of Regenerative Medicine and Immunotherapy, rivoceranib plays a fascinating role in changing the “tumor microenvironment.” Tumors typically create chaotic, leaky blood vessels that make it hard for the body’s natural immune cells (or engineered stem-cell therapies) to reach the cancer. Research from 2024 and 2025 shows that by blocking VEGFR2, rivoceranib temporarily “normalizes” the blood vessels. This creates a smoother pathway, allowing regenerative immune cells and checkpoint inhibitors to flood into the tumor and attack it more efficiently.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Baseline Blood Pressure: To ensure blood pressure is well-controlled before starting.
• Liver Function Tests (LFTs): To check baseline AST, ALT, and bilirubin levels.
• Urinalysis: To check for pre-existing protein in the urine.
• Complete Blood Count (CBC) and Coagulation Panel: To assess bleeding risks.

Precautions During Treatment

• Surgery and Wound Healing: Because the drug stops new blood vessels from forming, it can stop wounds from healing. You must stop taking rivoceranib several weeks before any planned surgery or dental work.
• Bleeding Risks: Avoid blood thinners, aspirin, or ibuprofen unless specifically approved by your oncologist.

“Do’s and Don’ts” List

• Do monitor your blood pressure at home every single day.
• Do tell your doctor immediately if you vomit blood, have black/tarry stools, or experience sudden severe stomach pain.
• Do take your pill at the same time every day.
• Don’t take a double dose to make up for a missed one.
• Don’t walk barefoot or expose your hands to very hot water, to help prevent Hand-Foot Syndrome.

Legal Disclaimer

Standard medical information disclaimer: This guide is for educational and informational purposes only and does not constitute medical advice. Rivoceranib mesylate is an investigational medication in the United States and should only be used under the strict supervision of a licensed oncologist or healthcare professional participating in clinical trials or approved access programs. Always consult with your healthcare provider to discuss your specific diagnosis, treatment plan, and potential risks. This content reflects clinical data available as of 2026.